{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T22:04:04Z","timestamp":1768514644645,"version":"3.49.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,9]],"date-time":"2022-10-09T00:00:00Z","timestamp":1665273600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Public Health"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.jiph.2022.10.010","type":"journal-article","created":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T07:02:38Z","timestamp":1665644558000},"page":"1259-1264","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Effect of fluvoxamine on outcomes of nonhospitalized patients with COVID-19: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"15","author":[{"given":"Li-Chin","family":"Lu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chien-Ming","family":"Chao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shen-Peng","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8663-3161","authenticated-orcid":false,"given":"Shao-Huan","family":"Lan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6334-2388","authenticated-orcid":false,"given":"Chih-Cheng","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiph.2022.10.010_bib1","unstructured":"World Health Organization. https:\/\/covid19.who.int\/ Accessed on July 1, 2021."},{"issue":"3","key":"10.1016\/j.jiph.2022.10.010_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105924","article-title":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges","volume":"55","author":"Lai","year":"2020","journal-title":"Int J Antimicrob Agents"},{"issue":"18","key":"10.1016\/j.jiph.2022.10.010_bib3","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1056\/NEJMcp2009249","article-title":"Mild or moderate Covid-19","volume":"383","author":"Gandhi","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jiph.2022.10.010_bib4","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jmii.2020.02.012","article-title":"Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): facts and myths","volume":"53","author":"Lai","year":"2020","journal-title":"J Microbiol Immunol Infect"},{"issue":"15","key":"10.1016\/j.jiph.2022.10.010_bib5","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa2102685","article-title":"Bamlanivimab plus etesevimab in mild or moderate Covid-19","volume":"385","author":"Dougan","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jiph.2022.10.010_bib6","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa2029849","article-title":"SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19","volume":"384","author":"Chen","year":"2021","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jiph.2022.10.010_bib7","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1001\/jama.2021.0202","article-title":"Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial","volume":"325","author":"Gottlieb","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.jiph.2022.10.010_bib8","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2107934","article-title":"Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab","author":"Gupta","year":"2021","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jiph.2022.10.010_bib9","doi-asserted-by":"crossref","first-page":"5199","DOI":"10.1038\/s41380-021-01021-4","article-title":"Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study","volume":"26","author":"Hoertel","year":"2021","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.jiph.2022.10.010_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.652688","article-title":"Fluvoxamine: a review of its mechanism of action and its role in COVID-19","volume":"12","author":"Sukhatme","year":"2021","journal-title":"Front Pharm"},{"issue":"1","key":"10.1016\/j.jiph.2022.10.010_bib11","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41380-021-01309-5","article-title":"The acid sphingomyelinase\/ceramide system in COVID-19","volume":"27","author":"Kornhuber","year":"2022","journal-title":"Mol Psychiatry"},{"issue":"4","key":"10.1016\/j.jiph.2022.10.010_bib12","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1038\/s41380-021-01432-3","article-title":"Mechanisms of action of fluvoxamine for COVID-19: a historical review","volume":"27","author":"Hashimoto","year":"2022","journal-title":"Mol Psychiatry"},{"issue":"1","key":"10.1016\/j.jiph.2022.10.010_bib13","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1055\/a-1717-2381","article-title":"Neuropsychiatric drugs against COVID-19: What is the clinical evidence?","volume":"55","author":"Mueller","year":"2022","journal-title":"Pharmacopsychiatry"},{"issue":"1","key":"10.1016\/j.jiph.2022.10.010_bib14","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s00406-021-01326-z","article-title":"Old drug fluvoxamine, new hope for COVID-19","volume":"272","author":"Hashimoto","year":"2022","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"22","key":"10.1016\/j.jiph.2022.10.010_bib15","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1001\/jama.2020.22760","article-title":"Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial","volume":"324","author":"Lenze","year":"2020","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.jiph.2022.10.010_bib16","doi-asserted-by":"crossref","first-page":"ofab050","DOI":"10.1093\/ofid\/ofab050","article-title":"Prospective cohort of fluvoxamine for early treatment of coronavirus disease 19","volume":"8","author":"Seftel","year":"2021","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"10.1016\/j.jiph.2022.10.010_bib17","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1016\/S2214-109X(21)00448-4","article-title":"Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial","volume":"10","author":"Reis","year":"2022","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.jiph.2022.10.010_bib18","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.jiph.2022.10.010_bib19","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.jiph.2022.10.010_bib20","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3947\/ic.2021.0142","article-title":"Fluvoxamine treatment of patients with symptomatic COVID-19 in a community treatment center: a preliminary result of randomized controlled trial","volume":"54","author":"Seo","year":"2022","journal-title":"Infect Chemother"},{"issue":"5","key":"10.1016\/j.jiph.2022.10.010_bib21","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.4269\/ajtmh.21-1310","article-title":"Fluvoxamine for the early treatment of COVID-19: a meta-analysis of randomized clinical trials","volume":"106","author":"Guo","year":"2022","journal-title":"Am J Trop Med Hyg"},{"issue":"4","key":"10.1016\/j.jiph.2022.10.010_bib22","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.6269","article-title":"Fluvoxamine for outpatient management of COVID-19 to prevent hospitalization: a systematic review and meta-analysis","volume":"5","author":"Lee","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"5","key":"10.1016\/j.jiph.2022.10.010_bib23","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1111\/bcp.15126","article-title":"Safety and efficacy of fluvoxamine in COVID-19 ICU patients: an open label, prospective cohort trial with matched controls","volume":"88","author":"Calusic","year":"2022","journal-title":"Br J Clin Pharm"},{"issue":"17","key":"10.1016\/j.jiph.2022.10.010_bib24","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1007\/s40265-021-01620-z","article-title":"Casirivimab\/Imdevimab: first approval","volume":"81","author":"Deeks","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.jiph.2022.10.010_bib25","doi-asserted-by":"crossref","first-page":"n2422","DOI":"10.1136\/bmj.n2422","article-title":"Covid-19: Molnupiravir reduces risk of hospital admission or death by 50 % in patients at risk, MSD reports","volume":"375","author":"Mahase","year":"2021","journal-title":"BMJ"}],"container-title":["Journal of Infection and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034122002659?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034122002659?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T15:16:51Z","timestamp":1761751011000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1876034122002659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S1876034122002659"],"URL":"https:\/\/doi.org\/10.1016\/j.jiph.2022.10.010","relation":{},"ISSN":["1876-0341"],"issn-type":[{"value":"1876-0341","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of fluvoxamine on outcomes of nonhospitalized patients with COVID-19: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Public Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiph.2022.10.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences.","name":"copyright","label":"Copyright"}]}}